80 recruiting, 46 active not recruiting, 11 not yet recruiting, 5 completed. 91 Phase 2, 71 Phase 1, 18 Phase 3, 1 Early Phase 1.
Follow Multigated Acquisition Scan: new trials by email Literature Review of Multigated Acquisition Scan trials Research Report on Multigated Acquisition Scan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 76 | 2027-06-25 | 2026-10-22 |
| Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma Biospecimen Collection, Diagnostic Imaging Testing, Echocardiography Test - Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 31 | 2027-06-01 | 2026-10-22 |
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-08-11 |
| Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors Aldesleukin, Biospecimen Collection, Chest Radiography - Locally Advanced Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Stromal Tumor | Phase 2 | Not yet recruiting | Joal Beane | 59 | 2027-02-15 | 2026-10-13 |
| Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 122 | 2027-01-15 | 2026-10-07 |
| Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 244 | 2027-01-15 | 2026-10-20 |
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) Azacitidine, Bone Marrow Aspiration and Biopsy, Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 184 | 2027-01-04 | 2026-10-01 |
| Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Tacabrutideg, Sonrotoclax, Obinutuzumab - Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 30 | 2027-01-01 | 2026-10-21 |
| Testing Safe Doses of Anti-Cancer Medicines, 5-Flurouracil (5-FU) and Tretinoin (ATRA), Added to the Usual Cancer Treatment of Ependymoma Biospecimen Collection, Echocardiography Test, Fluorouracil - Childhood Posterior Fossa Ependymoma | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 70 | 2026-12-11 | 2026-09-30 |
| Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall Biospecimen Collection, Computed Tomography, Doxorubicin - Resectable Liposarcoma, Resectable Soft Tissue Sarcoma | Phase 3 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 228 | 2026-12-01 | 2026-09-16 |
| Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Richter Syndrome, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 32 | 2026-11-15 | 2026-10-02 |
| Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma Anti-GPC3-CAR Autologous T Lymphocytes, Biospecimen Collection, Computed Tomography - Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 1 | Suspended | Roswell Park Cancer Institute | 24 | 2026-11-15 | 2026-09-15 |
| Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-11-05 | 2026-10-08 |
| IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancer FH-STEAP1 IL-18 CAR T cells, Antiandrogen Therapy, Biospecimen Collection - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 1 | Not yet recruiting | Fred Hutchinson Cancer Center | 20 | 2026-10-31 | 2026-09-04 |
| FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 9 | 2026-10-15 | 2026-09-17 |
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer Biopsy Procedure, Biospecimen Collection, Echocardiography Test - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 36 | 2026-10-06 | 2026-10-16 |
| Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Recruiting | Uma Borate | 70 | 2026-10-01 | 2026-08-27 |
| Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration, Cytarabine - Core Binding Factor Acute Myeloid Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2026-09-28 | 2026-10-20 |
| Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection - Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 87 | 2026-09-24 | 2026-10-20 |
Showing 20 of 157. Sign in to see all of them.
Leukemia, Myeloid, Acute (36) · Myelodysplastic Syndromes (21) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (14) · Leukemia, Biphenotypic, Acute (12) · Burkitt Lymphoma (10) · Lymphoma, Large B-Cell, Diffuse (10) · Fallopian Tube Neoplasms (9) · Neoplasm Metastasis (9) · Ovarian Neoplasms (9) · Melanoma (8) · Lung Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (6) · Endometrial Neoplasms (6) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Myeloproliferative Disorders (6)
National Cancer Institute (NCI) (70) · Fred Hutchinson Cancer Center (23) · City of Hope Medical Center (14) · Children's Oncology Group (7) · Mayo Clinic (6) · OHSU Knight Cancer Institute (6) · Ohio State University Comprehensive Cancer Center (4) · Roswell Park Cancer Institute (4) · University of Washington (4) · Northwestern University (2) · SWOG Cancer Research Network (2) · Uma Borate (2) · AIDS Malignancy Consortium (1) · Alliance for Clinical Trials in Oncology (1) · Asrar Alahmadi (1)
United States (150) · Puerto Rico (21) · Canada (20) · Australia (8) · New Zealand (4) · South Korea (2) · Guam (1) · Israel (1) · Japan (1)
Ibrahim Aldoss (4) · Joyce F Liu (4) · Amandeep Salhotra (3) · Curtis A Lachowiez (3) · Amer M Zeidan (2) · Filippo Milano (2) · Funda Meric-Bernstam (2) · Rosa Nadal Rios, MD, PhD (2) · Sumithira Vasu, MD (2) · Adam J Esbenshade (1) · Adrienne Waks, MD (1) · Alain P Algazi (1) · Alan L Ho (1) · Alexandre Hirayama (1) · Alexandre V. Hirayama, MD (1)
PMID 37185961, PMID 23810467, PMID 25218906, PMID 26586415, PMID 29784747, PMID 32414848, PMID 32463741, PMID 33020646, PMID 33048619, PMID 34028986, PMID 34416167, PMID 34686472, PMID 35133871, PMID 35138919, PMID 35170751, PMID 35175355, PMID 35290101, PMID 36166727, PMID 36351402, PMID 36521030, PMID 36898933, PMID 36902217, PMID 37053535, PMID 37322121, PMID 37597578, PMID 37934000, PMID 38127487, PMID 38591867, PMID 38867582, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40343719, PMID 40611889, PMID 40685312, PMID 40721981, PMID 40802906, PMID 40865033, PMID 40873341, PMID 40902132, PMID 40966692, PMID 41066729, PMID 41213241, PMID 41671463, PMID 42013378, PMID 42101296, PMID 42131734
P30CA033572 (14), U10CA180886 (14), U10CA180820 (11), U10CA180868 (9), U10CA180888 (8), UM1CA186709 (8), UM1CA186689 (7), U10CA180821 (6), UM1CA186688 (5), UM1CA186644 (4), UM1CA186704 (4), P30CA015704 (3), P30CA060553 (3), UM1CA186691 (3), UM1CA186717 (3)